



21-22 November
**3rd LYMPHOMA
LEUKEMIA**
DIAGNOSIS FOR TARGETED THERAPY
2019

Major Sponsors



Sponsors



Aula Magna



Inscripciones:
formacion.iisfjd@fjd.es



Lymphoma/leukemia diagnosis for targeted therapy, 2019

Lymphoma diagnosis and targeted treatment is challenged by the introduction of new drugs and refinements in the definition of new entities. This FJD Symposium will cover new markers and opportunities for a precision lymphoma/leukemia medicine

Nov 21-22nd, 2019

Fundación Jiménez Díaz Madrid

Program

Thursday, Nov 21st

10:00-10:15: F. Rojo/P. Llamas/C. Ayuso (FJD): Welcome and Meeting introduction

10:15-10:45: B. Pro (Northwestern University Feinberg School of Medicine Chicago): Advances in T-cell lymphoma treatment

10:45-12:00: Clinical case discussion Forum

P. Ortiz (12O): New approved treatments for CTCL (MF/SS)

SM. Rodríguez-Pinilla (FJD): Subcutaneous Panniculitic T-cell lymphoma

R. Córdoba (FJD): T-cell lymphoma therapy

J. Cornago, D. Morillo, A. Trascasa (FJD): TP53+ CLL, the relevance of the clonal evolution

E. Askari (FJD): Ibrutinib in patients with Waldenström's macroglobulinemia

12:00-12:30: Coffee break

12:30-13:00: F. Fend (University of Tuebingen, Germany): Bone marrow biopsy in the diagnosis of myeloid disorders

13:00-14:00: Clinical case discussion Forum

F. Climent (Hospital Universitario de Bellvitge) : Chronic eosinophilic leukemia with PDGFRA rearrangement

F. Fend (University Hospital Tuebingen): Non LC histiocytosis with ALK rearrangement

J. Menarguez, J.L. Diaz-Crespo, M. Bastos (HUGM): CAR-T cell therapy

C. Santonja, C. Lacalle, F. Lobo (FJD): BIA-ALCL

14:00-15:00: Lunch

15:00-15:30: Guillermo Garcia-Manero (MDACC Houston): Breaking Myelodysplastic Syndrome

15:30-16:00: Juan Manuel Alonso Dominguez (FJD): Molecular developments in diagnosis and therapeutics of AML

16:00-17:45: Clinical case discussion Forum:

G. Garcia-Manero: NPM1 mutations define a specific subgroup of MD and MDS/MPN patients with favorable outcomes with intensive chemotherapy

P. Dominguez (HURJC): HHV8 associated disorders

J. Sanchez Garcia (HGV): Breast-implant associated lymphoma

M. Mollejo (HVS): MYD88 mutated B-cell lymphomas

I. Betancurt (FJD): Follicular lymphoma with Hodgkin features

M. Garcia, L. Prieto (HCU Lozano Blesa, Zaragoza): Granulomatous dermatitis associated with CMML

G. Olmedilla, M. Gasier (H La Paz): Follicular lymphoma, blastoid

Friday, Nov 22nd

09:00-09:30: PL Zinzani (University of Bologna): The role of checkpoint inhibitors in non-Hodgkin lymphoma

09:30-11:00: Clinical case discussion Forum

C. Bárcena, JM Sánchez-Pina (H12O): Diffuse Large B-Cell Lymphoma Treated with CAR-T Cells: Clinical and pathological effects

M. Rodríguez-Moreno (FJD): T-cell lymphoma signatures

M. Sanchez-Beato (HPdH): Mutational spectrum in R-CHOP resistant DLBCL

M. Piris (FJD): Mediastinal large B-cell lymphoma

A. Franganillo, D. Morillo, I. Betencour (FJD): Cutaneous reaction after checkpoint inhibitors

M. Jo (FJD): Childhood cutaneous marginal zone B-cell lymphoma

11:00-11:30: Coffee break

11:30-12:00: V. Spina (Istituto Oncologico della Svizzera Italiana (IOSI)): Liquid biopsy in lymphoma diagnosis and follow-up

12:00-13:00: Clinical case discussion Forum

JF. García (MDACC): Liquid biopsy in T-cell lymphoma

S. Montes-Moreno: Liquid biopsy in Large B-cell Lymphoma

V. Spina: Splenic marginal zone B-cell lymphoma

G. Salvatierra, P. Dominguez: Hodgkin lymphoma

13:00-13:30: R. Córdoba/SM. Rodríguez-Pinilla (FJD): REAL-T Study

Clinical case discussion Forum

Instructive lymphoma/leukemia cases presented by both clinicians and pathologists will be discussed along 5 different sessions.

In total more than 6 hrs. In principle, 25 cases will be selected from submitted proposals. Cases are expected to cover new areas of lymphoma/leukemia diagnosis and targeted treatment.

Scientific Committee: P. LLAMAS, F. ROJO, M. PIRIS, SM. RODRIGUEZ-PINILLA, R. CORDOBA